ASCP News & Statements
Consensus Statement on Recommendations for the Deprescribing of Psychotropic Medications
The consensus statement addresses a growing need in psychiatry: how to start medications safely and effectively, but also when to reassess, taper, or discontinue them. While prescribing practices are well codified in clinical guidelines, little structured guidance has...
Joint Statement on Federal Concerns About Psychotropic Medication Safety
March 26, 2025 The safety and efficacy of traditional antidepressants, antipsychotics, and mood stabilizers (such as lithium andsome anticonvulsants) and stimulant medications have been established through decades of rigorous research, randomized clinical trials,...
ASCP Statement on the Elimination of the Clozapine REMS
As of February 24, 2025, the FDA no longer expects prescribers, patients and pharmacists to participate in the risk evaluation and mitigation strategies (REMS) program for clozapine. This means pharmacies can dispense clozapine without knowledge of the patients...
Joint Statement on Federal Concerns About Psychotropic Medication Safety
The safety and efficacy of traditional antidepressants, antipsychotics, and mood stabilizers (such as lithium andsome anticonvulsants) and stimulant medications have been established through decades of rigorous research,randomized clinical trials, peer-reviewed...